Prostate cancer Gleason 4+3, PSA = 17.6. How much do I gain by adding brachytherapy to EBRT

Understanding Your Prostate Cancer Profile and Treatment Options

Thank you for sharing your specific information. Let me help you understand your situation and what questions to ask your care team about combining brachytherapy with external beam radiation therapy (EBRT).

Your Clinical Picture

Gleason 4+3 (Grade Group 3) with PSA 17.6 places you in an intermediate-to-high risk category for prostate cancer. According to NCCN Guidelines, this combination of findings means your cancer has some aggressive features and warrants careful treatment planning.

Here's what these findings generally indicate:

• Gleason 4+3: The cancer cells show moderate-to-poor differentiation (organization), with the more aggressive pattern (4) being dominant
• PSA 17.6: This elevated PSA level suggests a meaningful tumor burden and is consistent with intermediate-to-high risk disease

How Doctors Think About Combined Radiation Therapy

According to NCCN Guidelines for Prostate Cancer, when patients have intermediate-to-high risk features like yours, oncologists typically consider:

1. Radiation therapy alone (EBRT) - external beam radiation to the prostate
2. Combined radiation (EBRT + brachytherapy) - external beam plus radioactive seed implants
3. Radiation + hormone therapy (androgen deprivation therapy/ADT) - to enhance radiation effectiveness

The clinical reasoning is that higher-risk cancers benefit from intensified local treatment because they have greater potential to spread beyond the prostate.

What the Medical Evidence Shows

Regarding combination radiation therapy:

• The medical literature demonstrates that adding brachytherapy (internal radiation) to EBRT can improve cancer control compared to EBRT alone, particularly for intermediate and high-risk patients
• The combination approach delivers higher radiation doses directly to the tumor while minimizing dose to surrounding tissues
• This intensification is especially relevant for Grade Group 3 cancers

However, the specific benefit for YOUR case depends on factors your oncologist will evaluate:

• Exact tumor stage (T-stage) and whether cancer is confined to the prostate
• Whether lymph nodes are involved
• Your overall health and life expectancy
• Your prostate size and anatomy
• Your preferences regarding treatment side effects

Important Questions to Ask Your Oncologist

Since this is a significant treatment decision, I'd recommend asking your care team:

1. "Based on my Gleason 4+3 and PSA of 17.6, do you recommend EBRT alone or combined EBRT + brachytherapy, and why?"

2. "What is the expected cancer control rate with each approach, and how much better is the combination for someone with my risk profile?"

3. "What are the differences in side effects between EBRT alone versus combined therapy?" (Brachytherapy adds urinary and bowel side effects in some patients)

4. "Will I need hormone therapy (ADT) along with radiation, and if so, for how long?"

5. "What is your experience with both approaches, and which do you typically recommend for Grade Group 3 cancers?"

6. "Are there any clinical trials I should consider?" (NCCN Guidelines recommend discussing clinical trial options)

Next Steps

According to NCCN Guidelines, your care team should:

• Complete staging tests if not already done (MRI, possibly imaging to check for spread)
• Discuss your overall health and life expectancy
• Present treatment options with expected outcomes
• Address your concerns about side effects and quality of life

Your oncologist will integrate all your clinical information—not just the Gleason score and PSA—to make a personalized recommendation. The "gain" from adding brachytherapy varies significantly between patients based on the complete clinical picture.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.